Earnings call Q&A preparation: the questions analysts will ask, answered from your approved disclosures
Every likely analyst question forecast and answered from approved disclosures, each line cited.
See one case, screen by screen ↓The quiet period starts and the clock runs to results day. Investor relations has to read every sell-side preview, go back through the last eight calls and the peers’ calls, guess which questions the 18 covering analysts will actually ask, and write a short spoken answer for the CEO, CFO or CSO for each one — while the release and the prepared remarks are still changing draft by draft.
Most of the hours go on reading and drafting, not judgement. And the risk sits in single sentences: a readout given as a month when the public record says a half-year, a growth figure taken from release draft v6 when v7 says something else, an adjusted number with no pointer to the reconciliation. Legal has to find each one by reading the whole book, a few days before the disclosure committee locks it.
Estimated hours per quarter for the IR team, by hand and with the solution — the split shown on the solution’s own dashboard.
Six specialist agents read the notes and calls, rank the questions, draft, check and rehearse each answer; the IR lead reviews.
Northwind Bio reports its third quarter on Thursday, October 29. It is October 7, the quiet period has started, and an analyst wants a date for the VLT-302 readout that the company has never given. Here is what happens next, screen by screen, in the working solution.
Lena opens the solution 22 days before the call: release at 7:00 am ET, call at 8:30, 18 covering analysts, about 45 minutes of questions. 41 questions are predicted, 29 answers approved, 4 disclosure flags open, and 4 of the 11 likely questions rehearsed. The question matrix puts the Talmirex 2027 floor at 88% and high stakes — “prepare hardest”.
The Research Reader reads 19 analyst notes, two of them new since yesterday. The Transcript Analyst goes through eight of Northwind’s calls and six peer calls — 214 past questions, with who asked and how they were answered. Calder Pharma’s oral IL-23 Phase 3 results from October 5 are matched to Veltrimab, the Question Forecaster clusters 236 raw questions into 42, and a new question is drafted and checked before Lena sees it.
New likely question · 82%: “Calder showed oral IL-23 data on Monday. Does a once-daily pill change your view of Veltrimab above $20 billion in 2030?” Drafted with 3 citations; no disclosure flags.
The questions list shows each one in the analyst’s phrasing, with its probability, its stakes, the analysts most likely to ask it, the speaker who answers and the status of the answer. Sixteen sit above the 20% line; 26 long-tail questions are drafted in the book’s appendix.
“VLT-302 finished enrolling in September. When exactly do we see topline data — could it be the first quarter?” It is 64% likely, high stakes, and Dr. Maya Chen answers it. The reasons are on the screen: Anika Bose’s note of October 3, Victor Salas asking for “more precision on VLT-302 timing”, and the same question from Victor Salas on the Q2 call. Street notes make up 52% of the probability, past calls 30%, investor feedback 18%.
Anika Bose, Bluewater Equity Research: “We think topline could come as early as Q1 2027 and we will press for timing.”
The draft answer reads “We now expect topline results in March 2027.” The Disclosure Guard flags it as new material information and shows the public source beside it: the September 14 press release, furnished on Form 8-K, says topline results are expected in the first half of 2027. Lena clicks “Use the public wording”, every check turns green, and she approves the answer.
“Our public timing is ‘the first half of 2027’. A month is more precise than anything we have disclosed — it would be new material information if said on the call.”
The Rehearsal Coach asks Q-07 as Anika Bose would, times the answer against a 30-second target and throws a follow-up: “Has the data monitoring committee looked at unblinded data yet?” The card gives the opening line — “Enrolment is complete — 1,146 patients.” — two numbers to use, the bridge to ulcerative colitis as the next leg of the Veltrimab story, and the line not to cross.
Do not say: “Do not name a month or a quarter for the readout.”
Lena submits the book. Tomás runs the tie-out: every answer read, 188 numbers tied to release draft v7, adjusted measures checked against the reconciliation tables. One does not tie — Q-02 says Veltrimab grew 26%, a figure from draft v6, before the third-quarter rebate true-up; v7 says 24.1%. He takes the v7 number and signs: 188 of 188 numbers tie.
Two answers still carry wording that is not public. Q-03 says “For 2027 we expect a further decline of about 45%, with a floor near $2.5 billion”; the public wording is “We will give 2027 guidance in January, as we always do.” Q-06 mentions late-stage talks for an obesity asset. Priya takes the public wording for both and signs: no new material information, safe-harbour and non-GAAP references in place.
“Priya Raman cannot sign while answers carry wording that is not public. For each, the Disclosure Guard proposes the public wording.”
Before the lock, the committee sees the 12 answers with no IR approval yet — each cited and through the Disclosure Guard, finance and legal — and can approve them as they stand or send them back to Lena. Omar, who chairs it, approves and locks. The chain reads IR, finance, legal, disclosure committee: the first three signatures record their meaning as “reviewed and approved”, the last reads “Locked · book version 1.0”; version 1.0 holds 42 questions, 42 approved, no flags open, and the rehearsal cards go to the CEO, CFO and CSO.
“Locked for the call · changes need the disclosure committee.”
The same book, seen by the people who write it, check it, sign it and say it on the call.
Six specialist agents read the notes and calls, rank the questions, draft, check and rehearse each answer; the IR lead reviews.
Reads each analyst note and preview from the research aggregator export, and lists the questions, concerns and estimates in it — with the page.
Reads the last eight call transcripts and the peers’ calls; records who asked what, how the company answered, and which topics keep coming back.
Clusters raw questions from notes, transcripts, peer news and investor feedback, then ranks each by probability and sensitivity, with the analysts most likely to ask.
Drafts each answer only from the approved disclosure library and this quarter’s release and script — every sentence cited — plus a rehearsal card.
Checks every sentence before people see it: new material information, numbers that do not tie, forward-looking statements and non-GAAP measures — and proposes the public wording for each flag.
Plays the analysts in rehearsal — asks each question in their voice, times the answer and throws a follow-up.
Reviews; finance and legal sign. The agents propose; a named person decides.
The IR team can ask about the likely questions, the answers, the analysts or the public record — or tell it what to change. Every answer is cited.
What will analysts ask first?
The five most likely: Q4 in the raised guide (94%, Rachel Kim), Veltrimab growth mix (89%, Victor Salas), the Talmirex 2027 floor (88%, Rachel Kim), the Corventa negotiation (76%, Grace Liu) and 2027 gross-to-net (71%, Tom Hadley). Guidance usually comes first — it opened the Q2 call too, and Rachel Kim says she will ask what is embedded for Q4.
Is anything in the book new material information?
Yes — three draft sentences go beyond the public record. The sharpest is VLT-302: the draft names March 2027, but the company has only said “the first half of 2027”. Opening Q-07 so you can decide.
Add a rule: flag any date more precise than we have said publicly
Done. Every answer is now checked for dates more precise than the public record — a month or a quarter where only a half-year has been said. It already catches Q-07, where the draft says “March 2027”. The rule is on in Settings and recorded on the audit trail.
Which analysts are most focused on Talmirex?
Three, led by Rachel Kim of Harbor & Pike, who wants the 2027 floor and models $2.3 billion; Tom Hadley of Ashby Cole asks about international erosion, and Helen Marsh of Northgate about the margin effect. The public line is about 45% US erosion in 2026, with 2027 guidance in January.
13 screens from the working solution, on its sample data. Pick one to see it large.
Who signs, what every answer must pass and when the forecast re-ranks are settings. Answering only from approved sources, citing every sentence and flagging new material information are always on.
| Setting | Default | Choose from |
|---|---|---|
| Book owner | Lena Ortiz | Lena Ortiz · Sam Patel |
| Finance tie-out | Tomás Reyes | Tomás Reyes · Omar Haddad |
| Legal review | Priya Raman | Priya Raman — reviews for Regulation FD, forward-looking statements and non-GAAP measures |
| Disclosure committee | Thu Oct 22 · chaired by Omar Haddad | Thu Oct 22 · Fri Oct 23 |
| Put a question in the book from this probability | 20% | 10 · 20 · 30 % — lower ones go to the appendix |
| Tie every number to the latest release draft | On | On · off — re-checks all answers when a new draft arrives |
| Flag forward-looking statements without the safe-harbour reference, and non-GAAP measures without a reconciliation | On | On · off, each |
| Re-rank when peer news or a new note arrives | On | Watch these peers: Calder Pharma · Ostrava Therapeutics · Brightwell Biosciences |
Every figure is labelled: a target the solution is built to, an estimate, a typical published result, or a proven one.
“demo” = seen in the working solution, on its sample company, the fictional Northwind Bio · “target” = the design goal, measured in the live solution · “estimated” = the solution’s own estimate before deployment · Regulation FD and Regulation G are SEC rules, named here as context. People and analysts named on this page are characters in the working solution.
Software that helps investor relations predict the questions analysts will ask on the earnings call and prepare short, sourced answers for the CEO, CFO and other speakers. The Earnings Q&A Prep Studio adds agents that read the notes and past calls, rank the questions, draft and check every answer and run the rehearsal — and it ends in a Q&A book signed by finance, legal and the disclosure committee.
The Question Forecaster clusters raw questions from sell-side notes, past call transcripts, peer news and investor feedback, then scores each by probability and by what is at stake. Every probability shows its reasons and how much each signal contributed, it names the analysts most likely to ask, and people can overrule the ranking.
No. Licensed analyst notes are read only to predict the questions. Answers are drafted only from the approved disclosure library and this quarter’s release and script, and every sentence carries its citation.
The Disclosure Guard checks every sentence against the public record and the latest release draft. It flags anything more precise or newer than what is public, numbers that do not tie, outlook statements without the safe-harbour reference and adjusted measures without the reconciliation — and proposes the public wording. A person decides on every flag, and legal reviews before the book is locked.
A new release or remarks draft re-checks every answer, so a number from an older draft is flagged. Peer news or a new analyst note re-ranks the forecast; a new question is drafted and checked, and the book owner is told.
Yes. The Rehearsal Coach asks each likely question the way the analyst would, times the answer against a target and throws a follow-up. Each card holds the opening line, the numbers to use, the bridge and the line not to cross, and it only ever suggests approved wording.
Yes. The agents propose; people decide. The book owner approves each answer, only a person can clear a disclosure flag, finance and legal sign in order, and the disclosure committee locks the book. Every step is on the audit trail.
The Agentic Solution Engine builds and deploys it from your requirements — your disclosure policy, sign-off order, disclosure library and a past quarter’s notes and transcripts — and it goes live once every quality gate has passed. We will walk you through it on your own last quarter first.
Every sustainability questionnaire is answered from one evidence library, each answer cited, checked and approved by its owner.
1-min filmPolicy RadarEvery bill, rule and hearing that touches our medicines is read overnight and briefed, with sources, to the right policy lead.
1-min filmPitch TriageEvery partnering pitch read, scored and answered within days, with any earlier decision on the same asset brought back.
1-min filmWe’ll run the Earnings Q&A Prep Studio on your last quarter’s notes, transcripts and disclosures.